Skip to content

Author

Zongwu Lin

We have 1 of 78 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

A major focus of this review is antibody-drug conjugates (ADCs) targeting novel surface antigens, including HER2, HER3, and TROP2, which have demonstrated remarkable clinical efficacy in EGFR TKI-resistant settings.

Xin-Ran Chen, Jia-Qi Liang, Jun-Kan Zhu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.